Medicines Allowed in Teleconsultation in India: List O, A and B

List O is the safe floor. It comprises medicines available over the counter and those unlikely to cause harm if prescribed on history alone, and it can be used on a video, audio, or text consultation, at a first contact or a follow-up. Typical entries are simple analgesics and antipyretics, oral rehydration salts, common topical antifungals, lozenges, and basic nutritional supplements. If your teleconsultation service is a low-acuity triage line, this list will carry most of what it needs.

The clinical trap in List O is not the drug, it is the reassurance. Prescribing paracetamol for six days of fever over a text exchange is technically permitted and clinically poor. The guidelines set the outer boundary of what is allowed; they do not lower the standard of care expected of the practitioner. Your SOP should be explicit that a permitted prescription is not the same as an appropriate one, and that escalation to video or to physical review is always available.

Operationally, List O is also where patient expectation gets set. Patients who came expecting a prescription and left with advice to hydrate and observe will rate the consultation poorly unless someone explains why. Give the doctor a structured advice-only closure that generates a proper document, so the patient receives something with the hospital name and the doctor registration number on it rather than the sense of having paid for nothing.

List A is the tier where mode does real work. These medicines may be prescribed at a first teleconsultation only if that consultation was a video consultation, on the reasoning that seeing the patient gives the practitioner information an audio call cannot. The same medicines may also be re-prescribed as a refill during a follow-up for a condition already being managed. This is the single rule most often broken, usually not deliberately but because the consultation started as video, dropped to audio, and the record never said so.

That is why mode capture and prescribing control have to be wired together. If your system records mode as an attribute of the booking rather than of the session, it will authorise List A prescribing on consultations that were in fact conducted by voice. The correct behaviour is for the prescribing screen to read the actual session mode, and for a downgrade to audio to visibly withdraw the List A option with a short explanation rather than silently allowing it.

The refill pathway needs its own guard. A refill assumes an existing, ongoing treatment for a defined condition, and the guidelines contemplate a reasonable continuity rather than an indefinite one. Set a house rule on how far back a prior encounter can be and still support a refill, write it in the SOP, and enforce it in the software. Consultants will push on this. The correct response is a documented clinical policy, not an unlogged override.

List B exists for a specific situation: the patient is already under treatment for a condition, is now in a follow-up teleconsultation, and needs something added to what was prescribed at the in-person visit. It is an add-on tier, not a substitute for the original prescription, and it presumes an established treatment relationship for that condition. Used properly it removes a large volume of low-value physical visits for stable chronic patients.

The condition linkage is the part that has to be enforced. A patient on antihypertensives who develops a new dermatological complaint is not in a follow-up for that complaint, and List B does not open up because they happen to be a returning patient. Your episode model needs to carry condition, not just patient, or this rule cannot be applied by anything other than the doctor's memory at the end of a long clinic.

There is a documentation obligation that travels with List B. The record should show what was prescribed at the earlier in-person consultation, what is being added now, and why. A follow-up note that says continue same plus new medicine and nothing else leaves the reviewer unable to tell whether the addition was inside the tier or outside it. Structured prescribing rather than free-text is doing more work here than most clinicians realise.

The prohibited tier is the shortest to explain and the least negotiable. Medicines in Schedule X of the Drugs and Cosmetics Rules and substances covered by the Narcotic Drugs and Psychotropic Substances Act cannot be prescribed through a teleconsultation. There is no mode, no consultation type, and no clinical urgency that opens this door remotely. If the patient needs them, the consultation ends in a physical review, an admission, or a referral, and the record should say which.

This creates a genuine clinical problem in psychiatry, palliative care, and pain management, where remote follow-up is otherwise valuable and the medicines that matter most are exactly the ones excluded. The honest answer is a hybrid model: teleconsultation for assessment, counselling, dose discussion, and family support, with a scheduled in-person visit for the controlled prescription itself. Design the pathway that way from the start rather than discovering the constraint mid-programme.

Your pharmacy controls should assume that a prohibited-tier prescription will occasionally be attempted, whether by error or by a patient presenting an altered document. The narcotic register discipline your pharmacy already runs for in-person dispensing should extend to how it treats any teleconsultation-origin prescription, and a hard system block at the prescribing end is cheaper than a discovery at the counter.

A teleconsultation prescription has to carry the practitioner name, qualification, registration number, the patient identification, the date, and the medicine details in the same way a paper prescription does. The guidelines contemplate the practitioner providing a photograph, scan, or digital copy of a signed prescription, or an e-prescription, to the patient by email or a messaging route. What matters is that the document is attributable and unaltered, not that it was printed.

Digital signatures under the Information Technology Act 2000 give the strongest attribution, and a properly signed PDF is materially harder to dispute than a photograph of a signature. Many hospitals stop at the image because signature tokens are inconvenient. That convenience is being traded against evidential strength, and it is worth making the trade knowingly rather than by default. At minimum, generate the prescription from the system with a verifiable reference rather than letting doctors send phone photographs of handwritten slips.

One caution on the dispensing end. The regulatory position for online pharmacy sale in India has been unsettled for years, with draft rules discussed but the framework under the Drugs and Cosmetics Rules not resolved in the way practitioners often assume. Your hospital's obligation is to issue a valid prescription; do not build a workflow that implicitly promises the patient a legal home delivery route you have not confirmed.

Rules that exist only in an SOP will be followed on quiet days and abandoned on busy ones. The prescribing screen is where they have to live. The design that works is filtering rather than warning: when a doctor opens the medicine search inside a teleconsultation, show only what is permissible for this mode and this consultation type, with a clearly labelled way to see the rest and a reason field if they insist. Warnings after selection get dismissed. Absence from the list gets noticed.

Map your own formulary to the tiers rather than relying on a generic mapping. Brand-heavy Indian prescribing means the same molecule appears under many names, and a tier mapping applied at brand level will have gaps. Map at molecule level, then let brands inherit, and have the pharmacy and therapeutics committee sign the mapping the same way it signs the formulary. HealUDoc can hold that tier attribute against the drug master so the prescribing filter and the pharmacy both read the same source.

Then measure it. Count remote prescriptions by tier, count overrides with reasons, and count how many audio consultations produced a List A item. That last number should be zero, and if it is not, you have found either a training gap or a mode-recording defect. Review the numbers monthly with the medical advisory committee. A prescribing control nobody reports on will decay within two quarters.